Cargando…

Evaluation of polymyxin B AUC/MIC ratio for dose optimization in patients with carbapenem-resistant Klebsiella pneumoniae infection

Polymyxin B has been used as a last-line therapy for the treatment of carbapenem-resistant gram-negative bacterial infection. The pharmacokinetic/pharmacodynamic index (AUC/MIC) of polymyxin B has not been clinically evaluated, given that the broth microdilution method for polymyxin susceptibility t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Peile, Liu, Shaohua, Qi, Guangzhao, Xu, Min, Sun, Tongwen, Yang, Jing
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Microbiology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10477696/ https://www.ncbi.nlm.nih.gov/pubmed/37675417 http://dx.doi.org/10.3389/fmicb.2023.1226981

Ejemplares similares

Low performance of Policimbac® broth microdilution in determining polymyxin B MIC for Klebsiella pneumoniae
por: Rocha, Natália Conceição, et al.
Publicado: (2023)

An area under the concentration–time curve threshold as a predictor of efficacy and nephrotoxicity for individualizing polymyxin B dosing in patients with carbapenem-resistant gram-negative bacteria
por: Yang, Jing, et al.
Publicado: (2022)

Polymyxin B Etest Fails to Distinguish Carbapenem-resistant Enterobacteriaceae with Elevated Polymyxin B MICs
por: Kulengowski, Brandon, et al.
Publicado: (2017)

Polymyxin B Resistance in Carbapenem-Resistant Klebsiella pneumoniae, São Paulo, Brazil
por: Bartolleti, Flávia, et al.
Publicado: (2016)

Evaluation of traditional initial vancomycin dosing versus utilizing an electronic AUC/MIC dosing program
por: Mcgrady, Kerri A., et al.
Publicado: (2020)

Combined effect of Polymyxin B and Tigecycline to overcome Heteroresistance in Carbapenem-Resistant Klebsiella pneumoniae
por: Tian, Yuan, et al.
Publicado: (2021)

Therapeutic drug monitoring of vancomycin by AUC(τ)-MIC ratio in patients with chronic kidney disease
por: Khoei, Ahmad, et al.
Publicado: (2019)

Pharmacokinetics/pharmacodynamics of polymyxin B in patients with bloodstream infection caused by carbapenem-resistant Klebsiella pneumoniae
por: Yu, Zhenwei, et al.
Publicado: (2022)

Rapid Nanopore Assay for Carbapenem-Resistant Klebsiella pneumoniae
por: Niu, Haofu, et al.
Publicado: (2019)

Heteroresistance to Amikacin in Carbapenem-Resistant Klebsiella pneumoniae Strains
por: Zhang, Feiyang, et al.
Publicado: (2021)

Early use of polymyxin B reduces the mortality of carbapenem-resistant Klebsiella pneumoniae bloodstream infection
por: Liang, Qiqiang, et al.
Publicado: (2019)

The Efficacy and Influencing Factors of Polymyxin B in High-Level Carbapenem-Resistant Klebsiella pneumoniae Infections
por: Jia, Xuedong, et al.
Publicado: (2023)

1310. Implementation of AUC:MIC Pharmacy to Dose in an Academic Medical Center: A Pilot Study
por: Idusuyi, Ann-Marie, et al.
Publicado: (2020)

Discrepancy in Vancomycin AUC/MIC Ratio Targeted Attainment Based upon the Susceptibility Testing in Staphylococcus aureus
por: Eum, Seenae, et al.
Publicado: (2016)

Polymyxin B and fusidic acid, a novel potent synergistic combination against Klebsiella pneumoniae and Escherichia coli isolates with polymyxin B resistance
por: Chen, Shuying, et al.
Publicado: (2023)

Population Pharmacokinetics of Polymyxin B in Obese Patients for Resistant Gram-Negative Infections
por: Wang, Peile, et al.
Publicado: (2021)

1327. Vancomycin Dosing by AUC(24)/MIC in Comparison to Traditional Trough Dosing in Office Infusion Centers (OICs)
por: Luu, Quyen, et al.
Publicado: (2020)

Prevalence of Carbapenem-Resistant Hypervirulent Klebsiella pneumoniae and Hypervirulent Carbapenem-Resistant Klebsiella pneumoniae in China Determined via Mouse Lethality Tests
por: Hu, Dakang, et al.
Publicado: (2022)

Epidemiological characteristics and molecular evolution mechanisms of carbapenem-resistant hypervirulent Klebsiella pneumoniae
por: Han, Yu-Ling, et al.
Publicado: (2022)

2451. Synergistic Activity of Ceftazidime–Avibactam in Combination With Polymyxin B Against Carbapenem-Resistant Klebsiella pneumoniae
por: Borjan, Jovan, et al.
Publicado: (2018)

Resistance evolution of hypervirulent carbapenem-resistant Klebsiella pneumoniae ST11 during treatment with tigecycline and polymyxin
por: Jin, Xi, et al.
Publicado: (2021)

Analysis of a Refractory Case of Pediatric Meningitis Caused by Klebsiella pneumoniae Co-Resistant to Carbapenems and Polymyxins
por: Huang, Xu, et al.
Publicado: (2022)

Cell Membrane Remodeling Mediates Polymyxin B Resistance in Klebsiella pneumoniae: An Integrated Proteomics and Metabolomics Study
por: Chen, Xinyi, et al.
Publicado: (2022)

Emergence of Colistin Resistance in Carbapenem-Resistant Hypervirulent Klebsiella pneumoniae Under the Pressure of Tigecycline
por: Zhang, Yawei, et al.
Publicado: (2021)

Ceftazidime/avibactam Improves the Antibacterial Efficacy of Polymyxin B Against Polymyxin B Heteroresistant KPC-2-Producing Klebsiella pneumoniae and Hinders Emergence of Resistant Subpopulation in vitro
por: Ma, Xingyan, et al.
Publicado: (2019)

Non-clonal occurrence of pmrB mutations associated with polymyxin resistance in carbapenem-resistant Klebsiella pneumoniae in Brazil
por: Rodrigues, Ana Claudia Souza, et al.
Publicado: (2019)

1415. Implementation and Validation of a Vancomycin AUC/MIC Calculator and Dosing Protocol at a Large Community Hospital
por: Seddon, Megan, et al.
Publicado: (2018)

A Monocentric Retrospective Study of AUC/MIC Ratio of Vancomycin Associated with Clinical Outcomes and Nephrotoxicity in Patients with Enterococcal Infections
por: Katip, Wasan, et al.
Publicado: (2021)

In vitro Activity of Apramycin Against Carbapenem-Resistant and Hypervirulent Klebsiella pneumoniae Isolates
por: Hao, Mingju, et al.
Publicado: (2020)

Molecular epidemiology and mechanism of Klebsiella pneumoniae resistance to ertapenem but not to other carbapenems in China
por: Wang, Dongliang, et al.
Publicado: (2022)

Molecular Epidemiology and Risk Factors of Carbapenem-Resistant Klebsiella pneumoniae Infections in Eastern China
por: Zheng, Bing, et al.
Publicado: (2017)

Transporter Genes and fosA Associated With Fosfomycin Resistance in Carbapenem-Resistant Klebsiella pneumoniae
por: Wang, Yu-Ping, et al.
Publicado: (2022)

Heteroresistance Is Associated With in vitro Regrowth During Colistin Treatment in Carbapenem-Resistant Klebsiella pneumoniae
por: Wang, Yifan, et al.
Publicado: (2022)

Acquisition of Tigecycline Resistance by Carbapenem-Resistant Klebsiella pneumoniae Confers Collateral Hypersensitivity to Aminoglycosides
por: Chen, Hua-le, et al.
Publicado: (2021)

Genome-wide association study of Klebsiella pneumoniae identifies variations linked to carbapenems resistance
por: Pei, Na, et al.
Publicado: (2022)

Eugenol eliminates carbapenem-resistant Klebsiella pneumoniae via reactive oxygen species mechanism
por: Liu, Wei, et al.
Publicado: (2023)

Corrigendum: Molecular epidemiology and mechanism of Klebsiella pneumoniae resistance to ertapenem but not to other carbapenems in China
por: Wang, Dongliang, et al.
Publicado: (2023)

Dissemination and characteristics of carbapenem-resistant Klebsiella pneumoniae in nine district hospitals in southwestern China
por: Wang, Yonghong, et al.
Publicado: (2023)

Association between the AUC(0-24)/MIC Ratio of Vancomycin and Its Clinical Effectiveness: A Systematic Review and Meta-Analysis
por: Men, Peng, et al.
Publicado: (2016)

Outbreak report of polymyxin-carbapenem-resistant Klebsiella pneumoniae causing untreatable infections evidenced by synergy tests and bacterial genomes
por: Gomes, Marisa Zenaide Ribeiro, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_oda47tpr38tfmeaqlr688ga5gu